On June 3, 2022 Prognos Health and xCures reported a collaboration to enable real-world data access and insights for life science companies across multiple use cases (Press release, xCures, JUN 3, 2022, View Source [SID1234615503]). The multi-year agreement will enable linking and access to xCures de-identified data and Prognos healthcare data marketplace.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited about combining our respective capabilities to improve outcomes and drive powerful insights on gaps in care, therapy impact, and real-world patient outcomes in oncology," said Mika Newton, CEO of xCures. "We are focused on finding the right treatment for cancer patients and together we believe we can help accelerate that goal."

"Collaborating with xCures is a great example of how Prognos is solving for disconnected, siloed data that cannot interoperate and leaves an incomplete view of the patient, said Sundeep Bhan, founder and CEO of Prognos. "Providing the ability to combine patients’ data across all data types including lab, claims, pharmacy, EHR, mortality, and SDoH data is critical to improving patient outcomes in Oncology."

Prognos and xCures utilize Datavant’s Encrypted Token Technology, which enables HIPAA-compliant linking of de-identified patient records to exchange data seamlessly and securely throughout the Datavant ecosystem of partners.